三生国健: 三生国健：2025年第二次临时股东大会会议资料

Core Points - The company is holding a second extraordinary general meeting of shareholders in June 2025 to discuss several key proposals [1][8] - The meeting will ensure the rights of shareholders and maintain order, with specific rules for attendance and participation [2][4] Proposal Summaries - Proposal 1: The company plans to sign a licensing agreement with its affiliates and Pfizer Inc. for a dual-targeting antibody product, granting exclusive rights for development and commercialization outside mainland China [4][6] - Proposal 2: A supplementary agreement regarding the distribution of payments from Pfizer under the licensing agreement will be established, with a proposed distribution ratio of 30% for the company and 70% for its affiliate [6][7] - Proposal 3: The company intends to temporarily use surplus funds of 66.6282 million yuan from various projects to supplement working capital and adjust the investment amounts for specific projects, reducing one project’s funding from 400 million yuan to 320 million yuan and increasing another from 610 million yuan to 690 million yuan [7][8]